Skip to main content Back to Top
Advertisement

2/18/2020

Cefoxitin Sodium Injection

Products Affected - Description

    • Cefoxitin powder for solution for injection, Apotex, 1 gram, vial, 25 count, NDC 60505-0759-05
    • Cefoxitin powder for solution for injection, Apotex, 10 gram, vial, 10 count, NDC 60505-0761-04
    • Cefoxitin powder for solution for injection, Apotex, 2 gram, vial, 25 count, NDC 60505-0760-05
    • Cefoxitin powder for solution for injection, Fresenius Kabi, 2 gram, 20 mL vial, 25 count, NDC 63323-0342-25
    • Cefoxitin powder for solution for injection, Hikma, 1 gram, vial, 25 count, NDC 00143-9878-25
    • Cefoxitin powder for solution for injection, Hikma, 10 gram, vial, 10 count, NDC 00143-9876-10
    • Cefoxitin powder for solution for injection, Hikma, 2 gram, vial, 25 count, NDC 00143-9877-25
    • Cefoxitin powder for solution for injection, Sagent, 10 gram, vial, 10 count, NDC 25021-0111-99
    • Cefoxitin powder for solution for injection, Sagent, 2 gram, vial, 25 count, NDC 25021-0110-20
    • Cefoxitin powder for solution for injection, WG Critical Care, 2 gram, vial, 25 count, NDC 44567-0246-25
    • Cefoxitin powder for solution for injection, BBraun, 2 gram, 50 mL DUPLEX Drug Delivery System, 24 count, NDC 00264-3125-11
    • Cefoxitin powder for solution for injection, BBraun, 1 gram, 50 mL DUPLEX Drug Delivery System, 24 count, NDC 00264-3123-11

Reason for the Shortage

    • Apotex has temporarily discontinued cefoxitin vials.
    • BBraun has cefoxitin on allocation due to increased demand.
    • Fresenius Kabi did not provide a reason for the shortage.
    • Hikma did not provide a reason for the shortage. Hikma is not currently marketing cefoxitin 10 gram vials.
    • Sagent has cefoxitin on shortage due to increased demand and manufacturing delay.
    • WG Critical Care did not provide a reason for the shortage.

Available Products

    • Cefoxitin powder for solution for injection, Fresenius Kabi, 1 gram, 15 mL vial, 25 count, NDC 63323-0341-25
    • Cefoxitin powder for solution for injection, Fresenius Kabi, 10 gram, 100 mL bottle, 10 count, NDC 63323-0343-66
    • Cefoxitin powder for solution for injection, Sagent, 1 gram, vial, 25 count, NDC 25021-0109-10
    • Cefoxitin powder for solution for injection, WG Critical Care, 1 gram, vial, 25 count, NDC 44567-0245-25
    • Cefoxitin powder for solution for injection, WG Critical Care, 10 gram, vial, 10 count, NDC 44567-0247-10

Estimated Resupply Dates

    • Apotex has temporarily discontinued cefoxitin 1 gram, 2 gram, and 10 gram vials and the company cannot estimate when product will be available again.
    • BBraun has cefoxitin 1 gram and 2 gram DUPLEX bags on back order and the company cannot estimate a next release date.
    • Fresenius Kabi has cefoxitin 2 gram vials on back order and the company estimates a release date of mid-June 2020.
    • Hikma has cefoxitin 1 gram and 10 gram vials on back order and the company estimates a release date late-June to early-July 2020. The 2 gram vials are on allocation.
    • Sagent has cefoxitin 2 gram and 10 gram vials on back order and the company estimates a release date of April 2020.

Updated

Updated February 18, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. Created November 8, 2016 by Leslie Jensen, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins